Butyrate (Sodium/Calcium Butyrate) ： Crohn's Disease

Q: Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?

Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).

Q: How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?

Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Butyrate (Sodium/Calcium Butyrate)?

Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?

We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

結論

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

Key Study Findings

Randomized Controlled Trial n=140 Double-blind

Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …

Dose: None vs: placebo plus conventional therapy Outcome: clinical disease activity and fecal calprotectin 効果: None p=0.013

対象集団: IBD patients (60 Crohn's disease, 80 ulcerative colitis)

In Vitro

Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …

Dose: Low-dose and high-dose NaB vs: DSS-induced IBD mice; 5-ASA control Outcome: IBD symptom alleviation and ferroptosis inhibition 効果: None None

対象集団: DSS-induced IBD murine model

In Vitro

Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.

Dose: 5 mg/mL vs: LPS-treated cell models Outcome: Intestinal barrier function and gut microbiota 効果: None None

対象集団: Caco-2 cells, RAW264.7 macrophages, fecal fermentation

Other

Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …

Dose: None vs: None Outcome: Causal associations IBD → arthritis subtypes (MR) 効果: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA) <0.001 (AS); 0.007 (PsA)

対象集団: Mendelian randomization study of IBD and arthritis

Observational Study n=212

Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.

Dose: None vs: Healthy controls Outcome: CD-specific microbiome signatures (AUC 0.94) 効果: AUC 0.94 in external validation None

対象集団: Crohn's disease and ulcerative colitis patients

In Vitro

Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …

Dose: None vs: Untreated Crohn's disease microbiota Outcome: Gut microbiome modulation and inflammation 効果: None None

対象集団: Crohn's disease fecal microbiota in SHIME model

Key Statistics

研究数

200

参加者数

↑

Positive

グレード

Referenced Papers

Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota. RCT

Digestive and liver … 2026 5 件の引用

Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora. Other

Annals of medicine 2025 12 件の引用

Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota. Other

Nutrients 2025 7 件の引用

Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology. Other

Biomarker research 2025 6 件の引用

Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot study. Other

Translational research : … 2025 4 件の引用

Is the microbiome the answer to inflammatory bowel disease: systematic review. Systematic Review

Langenbeck's archives of … 2025 3 件の引用

Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: Evidence From Mediated Mendelian Randomization. Other

Mediators of inflammation 2025 2 件の引用

Gut Microbial Metabolite Crosstalk in Crohn's Disease: Network Pharmacology Unveils Dual-Axis Pathogenesis and Therapeutic Targets. Other

BioFactors (Oxford, England) 2025

Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA. Other

Frontiers in bioscience … 2025

An Engineered Butyrate-Derived Polymer Nanoplatform as a Mucosa-Healing Enhancer Potentiates the Therapeutic Effect of Magnolol in Inflammatory Bowel Disease. Other

ACS nano 2024 89 件の引用

Enhancing recovery from gut microbiome dysbiosis and alleviating DSS-induced colitis in mice with a consortium of rare short-chain fatty acid-producing … Other

Gut microbes 2024 32 件の引用

Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review. Systematic Review

Microbiological research 2024 31 件の引用

Butyrate attenuates intestinal inflammation in Crohn's disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis. Other

International immunopharmacology 2024 17 件の引用

Gut metabolome and microbiota signatures predict response to treatment with exclusive enteral nutrition in a prospective study in children with … Other

The American journal … 2024 11 件の引用

Surgery for Crohn's Disease Is Associated With a Dysbiotic Microbiome and Metabolome: Results From Two Prospective Cohorts. Other

Cellular and molecular … 2024 10 件の引用

Dietary Clostridium butyricum and 25-Hydroxyvitamin D3 modulate bone metabolism of broilers through the gut-brain axis. Other

Poultry science 2024 9 件の引用

Treatment of Active Crohn's Disease With Exclusive Enteral Nutrition Diminishes the Immunostimulatory Potential of Fecal Microbial Products. Other

Inflammatory bowel diseases 2024 5 件の引用

Nutritional Management in Stricturing Crohn's Disease: A Pilot Study. RCT

Nutrients 2024 3 件の引用

Cannabidiol can affect morphology, morphometry, enzymatic and microbial activity of rabbit digestive system. Other

Journal of animal … 2024

Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Review

Nutrients 2023 162 件の引用

Alteration of the Gut Microbiome in Inflammatory Bowel Disease. Review

Digestion 2023 71 件の引用

Butyrate reduces adherent-invasive E. coli-evoked disruption of epithelial mitochondrial morphology and barrier function: involvement of free fatty acid receptor 3. Other

Gut microbes 2023 29 件の引用

Interplay of gut microbiota and host epithelial mitochondrial dysfunction is necessary for the development of spontaneous intestinal inflammation in mice. Other

Microbiome 2023 28 件の引用

Fecal short chain fatty acids and urinary 3-indoxyl sulfate do not discriminate between patients with Crohn´s disease and ulcerative colitis … Other

Lipids in health … 2023 7 件の引用

The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management. Review

Gut microbes 2022 107 件の引用

Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients. Other

Gut microbes 2022 60 件の引用

Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial. RCT

Nutrients 2022 54 件の引用

Oral Microbiome of Crohn's Disease Patients With and Without Oral Manifestations. Other

Journal of Crohn's … 2022 23 件の引用

Eicosatetraynoic Acid and Butyrate Regulate Human Intestinal Organoid Mitochondrial and Extracellular Matrix Pathways Implicated in Crohn's Disease Strictures. Other

Inflammatory bowel diseases 2022 21 件の引用

Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease. Other

PloS one 2022 9 件の引用

Anaerostipes hominis sp. nov., a novel butyrate-producing bacteria isolated from faeces of a patient with Crohn's disease. Other

International journal of … 2021 17 件の引用

Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. RCT

Neurogastroenterology and motility 2020 176 件の引用

Early Postoperative Endoscopic Recurrence in Crohn's Disease Is Characterised by Distinct Microbiota Recolonisation. Other

Journal of Crohn's … 2020 50 件の引用

Luminal microbiota related to Crohn's disease recurrence after surgery. RCT

Gut microbes 2020 32 件の引用

Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Review

Frontiers in immunology 2019 3034 件の引用

Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. RCT

Gastroenterology 2019 276 件の引用

Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn's disease. Other

Scientific reports 2019 124 件の引用

Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. Other

Terapevticheskii arkhiv 2019 50 件の引用

Beneficial effects of nutritional supplements on intestinal epithelial barrier functions in experimental colitis models in vivo. Review

World journal of … 2019 45 件の引用

Nutritional regulators of intestinal inflammation. Review

Current opinion in … 2019 5 件の引用

Protective Mechanisms of Butyrate on Inflammatory Bowel Disease. Review

Current pharmaceutical design 2018 108 件の引用

Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis. Other

Journal of Crohn's … 2018 91 件の引用

Interactions between species introduce spurious associations in microbiome studies. Other

PLoS computational biology 2018 29 件の引用

Modulation of ruminal and intestinal fermentation by medicinal plants and zinc from different sources. Other

Journal of animal … 2018 15 件の引用

Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Other

Cell host & … 2017 399 件の引用

Butyrate-producing bacteria supplemented in vitro to Crohn's disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Other

Scientific reports 2017 391 件の引用

Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. Other

Gastroenterology 2017 335 件の引用

Lifestyle alters GUT-bacteria function: Linking immune response and host. Review

Best practice & … 2017 14 件の引用

Autophagy counters LPS-mediated suppression of lysozyme. Other

Innate immunity 2017 13 件の引用

Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. Other

Digestion 2016 522 件の引用

Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India. Review

Journal of gastroenterology 2016 49 件の引用

Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. Systematic Review

Inflammatory bowel diseases 2015 222 件の引用

The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Other

Proceedings of the … 2014 1853 件の引用

A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Other

Gut 2014 1657 件の引用

Butyricicoccus pullicaecorum in inflammatory bowel disease. Other

Gut 2013 311 件の引用

Faecalibacterium prausnitzii and Crohn's disease - is there any connection? Other

Polish journal of … 2013

Butyrate attenuates lipopolysaccharide-induced inflammation in intestinal cells and Crohn's mucosa through modulation of antioxidant defense machinery. Other

PloS one 2012 108 件の引用

Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Other

Gut 2011 1055 件の引用

Oral butyrate for mildly to moderately active Crohn's disease. Other

Alimentary pharmacology & … 2005 227 件の引用

Review article: nutrition and adult inflammatory bowel disease. Review

Alimentary pharmacology & … 2003 179 件の引用

Nutrition in inflammatory bowel disease. Review

Current opinion in … 2001 45 件の引用

Nutrition in inflammatory bowel disease: impact on disease and therapy. Other

Current opinion in … 2001 38 件の引用

Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Other

Gut 2000 370 件の引用

Nutrition in inflammatory bowel disease. Review

Current opinion in … 2000 21 件の引用

Mucosal metabolism in ulcerative colitis and Crohn's disease. Other

Diseases of the … 1998 26 件の引用

Butyrate increases colonocyte protein synthesis in ulcerative colitis. Other

The Journal of … 1994 29 件の引用

Pharmacotherapy of inflammatory bowel disease. Review

Digestive diseases (Basel, … 1993 29 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:: 150-600 mg/day sodium or calcium butyrate
ibdsupport:: 300-600 mg three times daily (900-1,800 mg/day)
butyrateenema:: 100 mM butyrate enema for distal UC (clinical setting only)

上限量： No established upper limit for oral supplements; most studies use 600-4,000 mg/day

研究で検討された用量

用量	期間	効果	N
None	--	Positive	140
Low-dose and high-dose NaB	--	Positive	--
5 mg/mL	--	Positive	--
None	--	Positive	--
None	--	Positive	212
None	--	Positive	--
None	--	Negative	--
None	--	Mixed	--

推奨摂取タイミング： With meals; enteric-coated formulations recommended to reach the colon

Safety & Side Effects

報告されている副作用

⚠ Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
⚠ Mild GI discomfort (nausea, bloating)
⚠ Belching with butyric acid odor
⚠ Enteric-coated formulations reduce taste issues

既知の相互作用

● 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
● No significant adverse drug interactions known

耐容上限摂取量： No established upper limit for oral supplements; most studies use 600-4,000 mg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?

Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).

How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?

Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Butyrate (Sodium/Calcium Butyrate)?

Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?

We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

に関する他の成分： Crohn's Disease

Omega-3 Fatty Acids (EPA/DHA) C L-Glutamine C Curcumin C

Butyrate (Sodium/Calcium Butyrate) 他の症状・状態について

Ulcerative Colitis (UC) C

総合評価

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

Evidence Strength52%

Moderate confidence

研究の内訳

RCT (6)Meta (0)Other (0)

代替成分との比較

この症状に対する他の成分との比較をご覧ください。

に関するすべての成分を見る： Crohn's Disease

詳しく見る

FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。